Ikarian Capital, LLC Cara Therapeutics, Inc. Call Options Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 17, 2021	BUY	$15.07 - $21.71 $8.21 Million - $11.8 Million	544,900 Added 180.61%	846,600 $18.4 Million
Q4 2020 Feb 12, 2021	BUY	$12.72 - $16.16 $3.1 Million - $3.94 Million	243,700 Added 420.17%	301,700 $4.57 Million
Q3 2020 Nov 16, 2020	BUY	$12.34 - $17.92 $473,856 - $688,128	38,400 Added 195.92%	58,000 $738,000
Q1 2020 May 15, 2020	BUY	$9.12 - $17.78 $17,328 - $33,782	1,900 Added 10.73%	19,600 $259,000
Q4 2019 Jan 31, 2020	BUY	$16.11 - $25.98 $285,147 - $459,846	17,700 New	17,700 $285,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.7M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.